Amplicore closed its series seed round of funding at $4 million. Proceeds will allow the company to complete preclinical development of its two leading products, AM3101 and AM1101 injectables, and position the company for the next round of financing.
Amplicore is pursuing a regenerative approach to treat joint osteoarthritis, cartilage damage, degenerative disc disease and acute meniscus tear. AM1101 is in development as a treatment for osteoarthritis designed to reduce pain, inhibit cartilage degradation and promote tissue regeneration of aberrant cartilage.
Amplicore is also leveraging a study on the healing of acute meniscal tear after surgical repair, supported by a grant from the U.S. Department of Defense. AM3101 technology has demonstrated promising preclinical results as a potential minimally invasive and regenerative approach to managing soft tissue injury.